
	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
JAKAFI net sales1	$	816,659	$	763,788	$	1,574,414	$	1,473,200
OPZELURA net sales2	449,736		164,499		592,751		283,204
ICLUSIG net sales	34,394		32,729		69,857		62,273
PEMAZYRE net sales	23,418		22,192		45,961		40,632
MINJUVI/MONJUVI net sales	53,686		31,131		102,913		60,682
NIKTIMVO net sales	60,309		36,154		115,397		49,767
ZYNYZ net sales	49,947		8,921		91,340		11,930
Total net sales	1,488,149		1,059,414		2,592,633		1,981,688
JAKAVI product royalty revenues	124,190		109,714		229,746		201,859
OLUMIANT product royalty revenues	38,479		33,482		74,886		64,282
TABRECTA product royalty revenues	6,691		6,632		12,673		13,045
Other product royalty revenues	5,330		1,287		8,577		2,553
Total product royalty revenues	174,690		151,115		325,882		281,739
Milestone and contract revenues	11,200		5,000		28,200		5,000
Total revenues	$	1,674,039	$	1,215,529	$	2,946,715	$	2,268,427

2 Second quarter 2026 OPZELURA net sales includes $246.0 million related to our agreement with CMS to resolve our litigation related to the application of Medicaid rebate rules to OPZELURA. Refer to Note 15 for further information.